Discovery of PF-07220060, a potent and selective CDK4 inhibitor

被引：1
|
作者：
Anders, Lars
Gallego, Gary
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-ND12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ND12
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Targeting CDK4 and CDK6: From Discovery to Therapy
    Sherr, Charles J.
    Beach, David
    Shapiro, Geoffrey I.
    CANCER DISCOVERY, 2016, 6 (04) : 353 - 367
  • [32] Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
    O'Brien, Neil A.
    McDermott, Martina S.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Loson, Oliver
    Chau, Kevin
    Jia, Weiping
    Kamranpour, Naeimeh
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Glaspy, John A.
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Discovery of pf-4217903-a highly potent and exquisitely selective c-met inhibitor
    Tran-Dube, Michelle
    Shen, Hong
    Nambu, Mitchell
    Pairish, Mason
    Jia, Lei
    Cheng, Hengmiao
    Hoffman, Jacqui
    Le, Phuong
    Johnson, Catherine
    Kania, Robert
    McTigue, Michele
    Grodsky, Neil
    Ryan, Kevin
    Parker, Max
    Yamazaki, Shinji
    Zou, Helen
    Christensen, James G.
    Cui, J. Jean
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [34] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
    Johnson, Douglas S.
    Stiff, Cory
    Lazerwith, Scott E.
    Kesten, Suzanne R.
    Fay, Lorraine K.
    Morris, Mark
    Beidler, David
    Liimatta, Marya B.
    Smith, Sarah E.
    Dudley, David T.
    Sadagopan, Nalini
    Bhattachar, Shobha N.
    Kesten, Stephen J.
    Nomanbhoy, Tyzoon K.
    Cravatt, Benjamin F.
    Ahn, Kay
    ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (02): : 91 - 96
  • [35] Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1
    Dow, Robert L.
    Li, Jian-Cheng
    Pence, Michael P.
    Gibbs, E. Michael
    LaPerle, Jennifer L.
    Litchfield, John
    Piotrowski, David W.
    Munchhof, Michael J.
    Manion, Tara B.
    Zavadoski, William J.
    Walker, Gregory S.
    McPherson, R. Kirk
    Tapley, Susan
    Sugarman, Eliot
    Guzman-Perez, Angel
    DaSilva-Jardine, Paul
    ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (05): : 407 - 412
  • [36] Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate
    Li, Yongtao
    Guo, Qingxiang
    Zhang, Chao
    Huang, Zhi
    Wang, Tianqi
    Wang, Xin
    Wang, Xiang
    Xu, Guangwei
    Liu, Yanhua
    Yang, Shengyong
    Fan, Yan
    Xiang, Rong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (15) : 3231 - 3237
  • [37] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor.
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER RESEARCH, 2022, 82 (12)
  • [38] Novel cyano pyridopyrimidines as potent and selective inhibitors of CDK4 and Ark5 kinases
    Akula, Balaiah
    Athuluri, Saikrishna
    Cosenza, Stephen C.
    Kumar, Vinay
    Reddy, E. Premkumar
    Reddy, M. V. Ramana
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [39] A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
    Zhang, Hua
    Yan, Shu
    Zhan, Yan
    Ma, Sheng
    Bian, Yicong
    Li, Shaorong
    Tian, Junjun
    Li, Guangze
    Zhong, Dafang
    Diao, Xingxing
    Miao, Liyan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [40] G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors
    Sorrentino, Jessica A.
    Bisi, John E.
    Roberts, Patrick J.
    Strum, Jay C.
    CANCER RESEARCH, 2016, 76
12345